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ENGLISH SUMMARY 
 
Treating acute and chronic pain often require opioids, one of the most potent and 
effective classes of analgesic drugs. However, their use is plagued by numerous and 
potentially severe side effects of the gastrointestinal (GI) system. Constipation is 
probably the most prevalent and bothersome symptom, but as opioids affect the whole 
gut, symptoms such as gastrointestinal reflux, nausea, bloating, abdominal pain, and 
straining during evacuation are all frequently reported by opioid users. Collectively, 
these side effects are termed opioid-induced bowel dysfunction (OIBD). The 
mechanisms behind OIBD rely on µ-opioid receptor activation in the enteric nervous 
system, which negatively affects GI motility, GI fluid secretion/absorption, and 
function of GI sphincters. Conventional laxatives are considered the golden standard 
in treating OIBD. Nevertheless, the efficacy of laxatives remains debatable, and many 
patients consider them insufficient in reliving their problems. Over the last years, 
newer pharmacological treatment options for OIBD has emerged, including co-
administrated peripherally acting µ-opioid receptor antagonists (PAMORAs). 
Whereas laxatives merely are considered a symptomatic treatment, PAMORAs 
specifically target the underlying mechanism of OIBD, by blocking µ-opioid 
receptors in the GI tract. To assess the effect of new pharmacological treatments of 
OIBD, e.g. PAMORAs, and to gain new insights into the pathological mechanisms of 
OIBD, validated outcome measures are essential. The purpose of this PhD project was 
to explore the applicability of subjective and objective methods to assess OIBD in 
clinical and research settings. This was done by evaluating the effect of the PAMORA 
naloxegol on experimentally induced OIBD. Thereby, we gained new insights into the 
pharmacodynamics of PAMORAs, in which part of the GI tract the effects of opioids 
and naloxegol are most profound, and what methods can be used show these effects.  
    Three studies compile this thesis. Study I (a literature review) discuss the strengths 
and limitations of currently applied and newer upcoming methods to assess the small 
bowel and colon in an objective manner. Study II (an experimental study divided into 
Study IIa and IIb) investigates the underlying mechanisms of naloxegol on OIBD by 
assessing GI symptoms via questionnaires, GI transit time and motility patterns via 
the 3D-Transit system, colonic fecal volume via magnetic resonance imaging (MRI), 
and anal sphincter function via anorectal manometry and the EndoFLIP system. 
Finally, Study III (a validation study) evaluates reliability of the 3D-Transit system.  
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    In Study II, 24 healthy participants were included in a 6-day treatment of oxycodone 
co-administered either naloxegol or placebo, in a double-blind randomized crossover 
design. Thus, we used an experimental OIBD model to assess the effect of a 
pharmacological compound to reverse OIBD symptoms. Compared to placebo, 
naloxegol significantly improved GI symptoms and stool form, decreased total GI- 
and colonic transit times, and improved response of the recto-anal inhibitory reflex 
(RAIR). There was no effect of naloxegol on colonic fecal volume, anal resting 
pressure or anal canal distensibility. Study III showed a good reliability of manually 
analyzed segmental transit times extracted from the 3D-Transit system, provided that 
the research staff who analyze the recordings were well trained and experienced in 
doing so.  
    In summary, self-assessed questionnaires, the 3D-Transit system, and anorectal 
manometry were useful and sensitive methods to quantify an effect of naloxegol on 
experimentally-induced OIBD. Future studies may apply these results in choosing the 
appropriate methods in the design of studies that evaluate OIBD, and the effect of 
pharmacological interventions to treat this condition. Our studies also indicate that 
further refinement of the MRI method may be needed in order to expand its 
applicability in studies of OIBD, and that it may be worth focusing on the assessment 
of RAIR when investigating how opioids and other pharmacological compounds 
affects anal sphincter function. 
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DANSK RESUMÉ 
 
Opioider er en vigtig del af den farmakologiske behandling af moderate og stærke 
smerter. Desværre er behandling med opioider forbundet med flere potentielt alvorlige 
gastrointestinale bivirkninger. Forstoppelse er den hyppigst forekommende 
bivirkning, men patienterne plages også ofte af mavesmerter, oppustethed, halsbrand, 
kvalme, og smerter ved afføring, idet opioider påvirker hele mavetarmsystemet. 
Samlet set kaldes disse bivirkninger for opioid-induceret tarmdysfunktion (OIBD). 
OIBD opstår når opioider binder til µ-opioid receptorerne i det enteriske nervesystem, 
hvilket har en negativ indvirkning på gastrointestinal motilitet, gastrointestinal 
væskeabsorption og sekretion samt funktionen af de gastrointestinale sfinktere.  
     Forebyggelse og behandling af OIBD tager som regel udgangspunkt i laksantia. 
Ofte er behandling med laksantia dog ikke tilstrækkeligt effektivt, og kan i sig selv 
give bivikninger såsom oppustethed og mavesmerter. I de senere år er der udviklet 
flere behandlingsmuligheder af OIBD, blandt andet perifert virkende µ-opioid 
antagonister. Hvor laksantia udelukkende regnes for at være symptombehandling, 
blokerer disse antagonister µ-opioid receptorerne i det enteriske nervesystem, og er 
derved målrettet de underliggende patofysiologiske mekanimser af OIBD. Både i 
kliniske og forskningmæssige sammenhænge er valide subjektive og objektive 
metoder vigtige for at kunne undersøge effekten af nye farmakologiske 
behandlingsmuligheder af OIBD. Formålet med de gennemførte studier var at få ny 
indsigt i den farmakodynamiske virkning af naloxegol (en perifert virkende µ-opioid 
antagonist), samt at få ny viden omkring hvilke metoder der bedst kan bruges til at 
vurdere de patofysiologiske mekanismer bag OIBD og effekten af farmakologiske 
behandlinger heraf. 
    Studie I (et review) diskuterer fordele og ulemper ved objektive metoder der kan 
benyttes til at måle motilitet i tynd- og tyktarm. Studie II undersøger effekten af 
naloxegol på eksperimentelt induceret OIBD, ved hjælp af validerede spørgeskemaer 
og følgende objektive effektmål; transit tid og motilitet i tyktarmen, volumen af fæces 
i tyktarmen samt funktionen af analkanalen, målt med henholdsvis 3D-Transit 
systemet, MR og anorektal manometri. Studie III undersøger reproducerbarheden af 
transit tider målt med 3D-Transit systemet. 
    I Studie II modtog 24 raske forsøgspersoner en 6-dages behandling med oxycodon 
co-administreret enten naloxegol eller placebo, i et dobbelt-blindet, randomiseret 
overkrydsningsstudie. Forsøgspersonerne havde færre gastrointestinale symptomer, 
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oplevede mindre hård afføring, havde kortere transit tid i tyktarmen samt havde en 
øget afslapning af den interne anale sfinkter i forbindelse med rektal udvidelse (og 
dermed et øget respons af den anorektale inhibitoriske refleks) under naloxegol 
behandlingen, sammenlignet med placebo. Der var ingen effekt af naloxegol på 
fæcesvolumen i tyktarmen, og heller ingen effekt på hviletrykket i analkanalen eller 
på analkanalens eftergivelighed. Studie III viste en god reproducerbarhed af manuelt 
analyserede transit tider optaget med 3D-Transit systemet, forudsat at disse blev 
analyseret af erfarent forskningspersonale.  
    Disse studier viser at spørgeskemaer, 3D-Transit systemet og anorektal manometri 
var brugbare og sensitive metoder til at kvantificere effekten af naloxegol på 
eksperimentelt induceret OIBD. Fremtidige studier kan gøre brug af disse resultater i 
studiedesignet af nye forsøg der undersøger OIBD. Derudover lægger studierne op til 
at videreudvikle MR metoden til at undersøge fæcesvolumen i OIBD patienter, samt 
at fokusere på metoden til at måle den anorektale inhibitoriske refleks når man ønsker 
at se på lægemidlers effekt på analkanalens funktion under opioid-påvirkning.  
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CHAPTER 1   INTRODUCTION 
 
Pain is one of the most frequent symptoms presented in the primary and secondary 
health care system. It is estimated that around 20% of the general adult population 
suffer from chronic pain, and treating chronic pain is notoriously difficult.1,2 Moderate 
to severe pain often require opioids, one of the most potent classes of drugs used for 
pain management. The past few decades has seen an alarming rise in opioid 
prescriptions, a fact commonly referred to as the “opioid epidemic”.3 The escalating 
amount of opioid prescriptions increase the risk of patients experiencing numerous 
side effects. The more serious side effects relates to the central nervous system, and 
include sedation, respiratory depression, and impaired cognition.4 However, opioids 
also affect the periphery, and perhaps the most common side effects of all are the 
gastrointestinal (GI)-related ones. Opioid-induced constipation is considered the most 
prevalent and bothersome side effect, occurring in 40-86% of all chronic opioid users 
(depending on opioid dose, type and formulation).5,6 Nevertheless, as opioids affect 
the entire GI tract, more uncharacteristic symptoms such as gastro-oesophageal reflux, 
nausea, abdominal pain, bloating, and defecation problems are just as common.7 
Collectively, all GI side effects related to opioid treatment are termed opioid-induced 
bowel dysfunction (OIBD). Despite a very common phenomenon, health care 
providers seems to underestimate the high incidence rate of OIBD,8 probably due to 
lack of awareness and, until now, absence of a universal diagnostic criteria.9 OIBD 
was recently defined by the Rome IV criteria as a worsening in bowel habits after 
initiating opioid therapy, characterized by two or more of the following; reduced stool 
frequency, development or worsening of straining, a feeling of incomplete evacuation, 
and harder stool form.10  
 
1.1   PATIENT BURDEN OF OIBD 
 
Tolerance towards OIBD rarely develops over time, and may therefore be an 
undesirable travelling companion throughout the course of opioid treatment,11 and 
OIBD severity seems to increase with age.12 These GI side effects may reduce health-
related quality of life, and burden patient’s daily activities and social life to the extent 
of opioid dose reduction, non-adherence, and treatment discontinuation.13,14 In fact, 
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an internet-based survey from 2009, reported that 33% of patients felt the need to 
decrease the dose or stop using opioids due to OIBD.5 GI dysfunction is generally 
considered a taboo in the Western World and unfortunately, the severe psychological 
burden of OIBD is often misjudged by health care providers which may compromise 
patient care and medical compliance.15,16 Persistent constipation in relation to OIBD 
may have serious consequences due to the risk of colonic distension, gut perforation, 
and ileus, and is also associated with increased mortality.17 The socioeconomic 
implications of OIBD are correspondingly significant.18 A recent register-based 
cohort study of 97.169 opioid users in Denmark showed that non-cancer patients with 
OIBD had 34% higher healthcare costs compared to those without.19 Despite all this, 
a strong reliance on opioids for pain management for various acute and chronic pain 
conditions remain.  
 
1.2   PATHOPHYSIOLOGY OF OIBD 
 
The GI tract is composed of smooth muscle arranged in a longitudinal and circular 
layer, both innervated through the enteric nervous system (ENS). The ENS regulates 
sensory, motor, and secretory effects of the whole GI tract. Opioid receptors are 
localized at the myenteric and submucosal neurons in the ENS.20 Three main opioid 
receptor classes are expressed; µ (mu), κ (kappa), and δ (delta), all of which are G-
protein-coupled receptors. Of these, the µ-opioid receptors are the most widely 
distributed, and also the most important receptor in relation to OIBD.21 The main 
effect of µ-opioid receptor activation is thought to be decreased formation of cyclic 
adenosine monophosphate, which leads to decreased neuronal excitability, and 
thereby, inhibition of cell activity.22 Under normal physiological conditions, 
endogenous opioids regulate and coordinate normal GI functions via these 
mechanisms; however, opioid receptors are also affected by exogenously 
administered opioids.21 Exogenous opioids affect GI motility in multiple negative 
ways. In the stomach, opioids are believed to increase tonic contraction of the antrum 
and impair muscle tone of the gastric reservoir,23 leading to delayed gastric emptying 
as demonstrated in multiple studies.24–26 In the small bowel and colon, opioids directly 
induce non-propulsive contractions by inhibition of neurotransmitters in the smooth 
muscle cells. In the circular muscle layer this facilitates stronger and more frequent 
phasic, non-migrating muscle contractions called “spike bursts”, which leads to an 
increased contractile tone and reduced propulsive contractions of the longitudinal 
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muscle layer.27 Furthermore, opioids possibly cause GI dysmotility through the 
suppression of local acetylcholine release via central nervous system-stimulated 
sympathetic overflow to the intestines.23,28 All together, these effects delay oro-cecal 
and colonic transit time as confirmed by several studies. 25,29–31 Furthermore, a recent 
study found that opioids reduce the number of mass movements in colon.32 Water and 
electrolyte secretion is also decreased as opioids inhibit the formation of cyclic AMP, 
acetylcholine and vasoactive peptide production. This inactivates chloride channels 
causing a disruption in the osmotic gradient across the gut lumen leading to less water 
secretion.33 This makes fecal content dry and difficult to pass. Opioids also cause less 
gastric- and pancreatico-bilary secretion leading to altered digestion and decreased 
bioavailability of drugs.34 Lastly, opioids may also increase the tone of GI sphincters, 
although the mechanisms behind this are not fully understood.35 Opioids have been 
associated with increased lower esophageal sphincter resting pressure,36 and increased 
tone of the Sphincter of Oddi which may give rise to colicky upper abdominal 
pain.37,38 Studies on how opioids affect the anal sphincter are scarce and inconsistent, 
however associations to increased rectal threshold volumes for minimum perception, 
and diminished recto-anal inhibitory reflexes (RAIR) have been found.39 The RAIR 
is an important part of defecation which is severely impaired in the absent of RAIR 
as in e.g. Hirschprungs’ disease.40 The theory of opioids diminishing RAIR is 
supported by the experiences of opioid users who often complain about straining, 
incomplete evacuation, and a sensation of anal blocking.41 All these opioid effects in 
the GI tract may manifest as the previously described diverse and multifaceted OIBD 
symptoms.  
 
1.3   PREVENTION AND TREATMENT OF OIBD 
 
As OIBD covers a group of various GI side effects, and is not a condition in itself, the 
treatment regimen is often difficult. Lifestyle changes such as increasing daily fibre 
intake and physical activity are often recommended, although there is little evidence 
that these factors may improve constipation in general.42 Thus the prophylaxis and 
management of OIBD rely heavily on conventional laxatives.43 When this is 
ineffective or insufficient, peripherally acting µ-opioid receptor antagonists 
(PAMORAs), a fixed dose of oxycodone:naloxone,44 or the secretagogue lubiprostone 
(activator of the chloride channel) may be considered.45 Furthermore, Prucalopride, a 
5-HT4 agonist, also seems to improve OIBD symptoms, although not currently 
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approved for this indication.46 In the next chapters, the use of conventional laxatives 
and PAMORAs to treat OIBD is discussed.  
 
1.3.1   LAXATIVES 
 
The primary effects of laxatives are to increase the osmotic gradient (e.g. lactulose 
and sorbitol), and/or stimulate the colonic musculature (e.g. bisacodyl and sessosides). 
Laxatives are the standard treatment for constipation, although their efficacy often is 
unsatisfactory.47 The efficacy of laxatives on OIBD is also debatable. Thus, some 
patients do benefit from them, but for a large group of patients, the GI symptoms 
remain a persistent struggle that increases the ongoing burden of chronic pain.13,48 
This became clear in a multinational survey of 322 chronic opioid users, in which 81% 
still reported numerous GI side effects despite concomitant laxative use.49 Likely, the 
explanation is that opioids affect the entire GI tract whereas laxatives mainly exert 
their effect in the colon. Hence, laxatives have no effect on dysmotility and secretory 
changes in the stomach and small bowel, and do not exert any effect on GI sphincter 
function. Overall, laxatives are merely considered a symptomatic treatment of OIBD, 
as the underlying pathology is not targeted. Furthermore, laxatives are known to 
worsen GI symptoms, and in itself cause abdominal pain, bloating, gas and reflux 
symptoms.50  
 
1.3.2   PERIPHERAL OPIOID ANTAGONISTS 
 
PAMORAs is a group of newer pharmacological agents designed to relive or reverse 
undesired opioid GI side effects. Currently, four PAMORAs are marketed; alvimopan, 
methylnatrexone, naldemedine, and naloxegol. These are all drugs that specifically 
block µ-opioid receptors in the periphery with preservation of central analgesia 
(Figure 1).51 All have been approved for the indication of OIBD in patients with 
chronic non-cancer pain, except alvimopan, which is merely approved in the US to 
decrease the time to GI recovery following partial bowel resection surgery.52 
Methylnaltrexone is a derivative of naltrexone and the first PAMORA to be approved 
in 2008 by the US Food and Drug Administration (FDA) as a subcutaneous injection, 
and very recently as an oral formulation. It has been proved efficacious in terms of 
decreasing morphine-induced delay in oro-cecal transit time, increasing weekly stool 
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frequency, and overall improving defecation difficulties.53–56 Due to a quite strong 
effect, the drug must be used carefully, especially in patients with preexisting GI 
disease. Naldemedine, also a derivate of naltrexone, was recently approved in March 
2017 by FDA as an oral tablet. It has been found to increase the rate of stool 
frequencies per week in OIBD patients.57,58 Naloxegol is the drug of interest of this 
thesis, hence the pharmacodynamics and implications for this is described in details 
in the next section. 
 
 
Figure 1. µ-opioid receptors are present in the myenteric and submucosal plexuses of the 
enteric nervous system. When these receptors are activated, various gastrointestinal (GI) 
functions are affected. Peripherally acting µ-opioid receptor antagonists (PAMORAs) may 
alleviate these side effects by blocking opioids from the µ-opioid receptors.   
 
1.3.2.1   NALOXEGOL 
 
Naloxegol is a polyethylene glycol conjugated derivative of naloxone, restricted to 
the periphery via two mechanisms; 1) a large molecule size limits passive 
permeability through the blood-brain barrier, and 2) it is a substrate of the P-
glycoprotein transporter, a gatekeeper in the blood-brain barrier.59 Thereby naloxegol 
molecules stay for a long time in the systemic circulation. In 2014, the FDA approved 
naloxegol as treatment of OIBD in patients with chronic non-cancer pain, and the 
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European Medicines agency approved it for patients with inadequate response to 
laxatives. Naloxegol was approved following a series of large clinical trials in patients 
with OIBD (called the KODIAC studies), showing a dose-dependent therapeutic 
efficacy in terms of increasing weekly stool frequency, improving time to first bowel 
movement, and decreasing patient-reported GI symptoms.60–62 The latter revealed 
improvements in straining, stool form, feeling of evacuation completeness, and not at 
least, improvement in psychical and social functioning. In general, naloxegol is 
considered well-tolerated, and is proven safe in relation to e.g. cardiac side effects and 
mild-moderate renal/hepatic failure.63–66 An overview on efficacy and safety 
outcomes in clinical trials of naloxegol is provided in Table 1. 
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Table 1. Overview on studies on the safety and efficacy of naloxegol. H: Healthy participants; 
P: Patients; DB: Double-blind; OP: Open-label; PGP: P-glycoprotein; PAC-SYM: The patient 
assessment of constipation symptoms questionnaire; PAC-Qol: The patient assessment of 
constipation quality of life questionnaire; SF-36: The Short Form (36) Health Survey.  
Author Phase H/P, n Study design Safety/efficacy outcomes 
Gottfridsson et al.  
[2013]67 
1 H, 45 
DB, randomized, crossover 
2 days of naloxegol or 
placebo  
Naloxegol doses up to 150 
mg did not induce QT/QTc 
interval prolongation 
Bui et al. 
 [2014]66 
1 
P, 16  
H, 8  
OP  
Single naloxegol dose 
Hepatic impairment had no 
impact on 
pharmacokinetics and 
safety of naloxegol 
Bui et al.  
[2014]65 
1 
P, 24 
H, 8 
OP  
Single naloxegol dose  
Renal impairment had no 
impact on 
pharmacokinetics and 
safety of naloxegol 
Bui et al. 
[2016]68 
1 H, 87 
OP, non-randomized, 
crossover  
1-17 days of naloxegol co-
adm. ketoconazole, 
diltiazem or rifampin 
Ketoconazole and 
diltiazem (CYP3A 
inhibitors) increased 
naloxegol plasma 
exposure, while a CYP3A 
inducer (rifampin) reduced 
it 
Bui et al. 
[2016]69 
1 H, 38 
DP, randomized, crossover  
Single naloxegol dose co-
adm. quinidine or placebo 
Quinidine (a CYP3A 
inhibitor) increased 
naloxegol plasma exposure 
Webster et al.  
[2013]60 
 
2 P, 207  
DB, randomized, parallel 
4 weeks of naloxegol or 
placebo   
Naloxegol increased stool 
frequency, improved time 
to first bowel movement, 
and induced less symptoms 
Eldon et al.  
[2015]63 
 
2 H, 46 
DB, randomized, crossover  
Single naloxegol dose or 
placebo 
Morphine-induced delay in 
oro-cecal transit time was 
reversed by naloxegol 
Halawi et al.  
[2017]70  
2 H, 72 
DB, randomized, parallel  
3 days of codeine, 
naloxegol, 
codeine+naloxegol or 
placebo  
Codeine-induced delay in 
whole gut transit was not 
reversed by naloxegol  
Chey et al.  
[2014]61 
Tack et al.  
[2015]62 
Lawson et al. 
[2016]71 
 
3 P, 652  
DB, randomized, parallel  
12 weeks of naloxegol or 
placebo 
Naloxegol increased stool 
frequency and form, 
improved time to first 
bowel movement, induced 
less GI symptoms, and 
improved straining 
Webster et al.  
[2014]64 
 
3 
P, 804  
 
OP, randomized, parallel  
52 weeks of naloxegol or 
usual care 
Long-term administration 
of naloxegol was safe and 
well- tolerated 
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CHAPTER 2   RATIONALS AND AIMS 
 
At present, there is no consensus as to which tool should be used for the assessment 
of OIBD, either in clinical practice or in research. Choice of approach also reflects the 
somewhat different purposes of the two settings. In clinical practice, the diagnosis and 
evaluation of OIBD severity is usually based on the patient’s perception of symptoms, 
i.e. anamnesis of defecation difficulties, abdominal pain, and health-related quality of 
life.43 Often, stool frequency is evaluated by the physician via e.g. the Bristol Stool 
Form Scale (BSFS), however this is primarily used as an affirmative diagnostic 
criteria for constipation, defined as less than three stools per week.72 In research, we 
seek to understand the underlying mechanisms of OIBD and/or efficacy of a 
pharmacological agent to treat it, instead of merely focusing on the treatment goal (i.e. 
reduction of OIBD-related pain, burden etc.). In the majority of research studies, 
efficacy outcomes like time to first bowel movement, change in laxative use, and stool 
frequency and is often used, the latter being the most common approach. Also, self-
reported questionnaires and more objective measures can provide a clearer picture on 
the diversity of GI symptoms, and work as valuable tools to assess pharmacological 
effects. A combination of the two is often considered, as there seems to be low 
correlation between subjectively assessed symptoms and objective evaluations such 
as transit time.73–75     
    Meaningful and valid objective methods to quantify degree of constipation and 
other OIBD symptoms remain elusive. The lack of validated outcome measures has 
been a great limitation in evaluating the efficacy of treatments that alleviate OIBD. 
By investigating the pharmacological effects of a PAMORA on OIBD, we may gain 
valuable insights into two main areas: 1) The utility of methods to assess OIBD, and 
2) PAMORA specific pharmacodynamics, i.e. how does this type of drug affect GI 
peristaltic patterns, GI secretion, and function of GI sphincters in the opioid-affected 
gut. Hence, the overall purpose of this PhD project was to explore the applicability of 
objective and subjective methods to assess the effect of naloxegol on experimentally 
induced OIBD. 
The thesis is based on four peer-reviewed papers compiling data from three studies; a 
literature review, an experimental study, and a validation study (Figure 2). The 
literature review (Study I) discusses strengths and limitations of established and 
emerging methods for evaluating GI motility. The experimental study investigates the 
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underlying mechanisms of naloxegol on OIBD, by assessing anal sphincter function 
(Study IIa), GI transit time, motility, and fecal load in colon (Study IIb). Finally, a 
validation study evaluates the repeatability of subjectively estimated GI transit times 
obtained from the 3D-Transit system (Study III). The four papers will from heron be 
referred to as named above. 
 
Figure 2. Overview on studies implemented in the thesis, and titles of corresponding papers.  
 
 
The study aims were:  
Study I:     To summarize procedures, indicattions, advantages, and disadvantages of                                                                                                   
currently available and upcoming methods for evaluation of small bowel and colonic 
motility. 
Study II:    To evaluate how naloxegol affected 1) anal resting pressure, 2) RAIR-
induced sphincter relaxation, 3) anal canal distensibility, 4) total and segmental GI 
transit times, 5) total and segmental colonic fecal volumes, and 6) self-assessed GI 
symptoms, during experimentally induced OIBD. 
Study III:    To assess the inter- and intra-rater repeatability of segmental GI transit 
times from the 3D-Transit system, and evaluate how the experience of the rater 
influences the identification of these time points. 
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CHAPTER 3   METHODS AND RESULTS 
 
Section 3.1 sums up the essence of Study I. The rationale behind Study II is followed 
by a short description of methods (section 3.2.1) and key results (section 3.2.2). 
Lastly, for Study III, rational, methods (section 3.3.1), and key results (section 3.3.2) 
are presented. Details are found in the corresponding papers.  
 
3.1   STUDY I 
 
GI dysmotily is a vague descriptive term used to describe disruption of normal 
contractility of the gut. In a broad sense, any alterations in the transit of food and GI 
secretions may be considered an intestinal motility disorder, which may have several, 
complex, underlying causes. In a large proportion of patients presenting with 
symptoms from the GI tract, it may be possible to detect and quantify dysmotility 
using various available methods, and thereby optimize treatment for these patients. 
Also, valid objective methods to assess the GI tract are highly important in research 
settings. This review outlined established and emerging methods to assess small 
bowel and colonic motility for clinical and research purposes. For the upper GI tract 
(esophagus and stomach), several standardized methods to evaluate motility exist; 
however assessing the more unapproachable small bowel and colon is quite 
cumbersome. In clinical settings, radiopaque markers, hydrogen breath tests and 
scintigraphy are commonly used for this purpose. Radiopaque markers are small 
pellets which are ingested, followed by an abdominal x-ray after a few days. By 
counting the number of remaining markers, colonic transit time may be estimated in 
a seemingly quick and inexpensive way. However, radiation exposure of the patient 
is a major drawback. Hydrogen breath tests may determine oro-cecal transit time 
through the measurement of hydrogen gases excreted in the breath after ingestion of 
a loading dose of lactulose. Data interpretation may however be difficult, as lactulose 
has a natural accelerating effect on small bowel transit. Scintigraphy is based on the 
oral ingestion of a radiolabeled meal followed by a gamma camera image of the 
abdomen to particularly determine colonic transit time. However, this method also 
include radiation expose of the participant. In addition, for all three methods applies 
that only transit time and not details on GI motility patterns is be assessed. In contrast, 
the wireless motility capsule (WMC, SmartPill®) and the 3D-Transit system represent 
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newer alternative approaches to assess both segmental transit times and motility 
patterns in an ambulatory and much less invasive way. The WMC qualifies regional 
GI transit time and GI motility patterns by measuring pH and intraluminal pressure. 
The former is highly useful clinically when classifying constipation, and the latter is 
predominantly used as a research tool to study dysmotility patterns. Nonetheless, 
WMC only provides a measure of whole colonic transit time and not regional. This is 
on the other hand possible with the 3D-Transit system. Here, changes in capsule 
rotations can be studied in respect to the anatomical position, which provides a direct 
measure of peristalsis and information about the direction, velocity and lengths of 
bowel contractions. The system is, at present, merely used in basic research. Other 
emerging techniques are high-resolution manometry for colonic dysmotility (which 
may replace conventional manometry in pending years), and magnetic resonance 
imaging (MRI) motility assessments. MRI is an exciting novel technique which has 
the potential to quantify both small bowel and colonic motility; however, these 
techniques are still in their infancies. A better understanding of several GI dysmotility 
disorders is highly needed, and therefore, data quality optimization, standardization, 
and patient-safety of both established and emerging techniques are warranted.  
 
3.2   STUDY II 
 
Many aspects on the underlying pathology and mechanism of treatment options on 
OIBD have yet to be described in detail. In the logic sense, restrictive blocking of 
peripheral µ-opioid receptors whilst undergoing opioid treatment would abolish the 
side effects related to the gut. Unfortunately, it is not that simple, as various factors 
may affect this outcome. By investigating the effect of naloxegol on many different 
subjective and objective aspects, a clearer picture of OIBD pathology may arise. This 
may also provide a better understanding of which methods are most relevant and 
sensitive to assess OIBD. An explorative crossover study employing an experimental 
model of OIBD in healthy males was chosen as the best possible way of addressing 
this. The OIBD model was previously established by our research group in which a 
5-day treatment of prolonged-release (PR) oxycodone in healthy participants 
increased GI transit time, increased colorectal volume, and induced substantial 
symptoms of OIBD, compared to placebo. These studies will from heron also be 
referred to as the studies by Poulsen et al.77 and Nilsson et al.78    
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3.2.1   METHODS 
 
3.2.1.1   STUDY DESIGN 
 
 
The study was conducted in compliance with the ICH-GCP principles of the European 
Union, and approved by the Danish Medicines Agency (reference no. 2015021429) 
and The North Denmark Region Committee on Health Research Ethics (reference no. 
N-20150014). It was designed as a double-blind, randomized, crossover trial. Twenty-
four healthy males from the age of 20-60 years with neither current GI symptoms, 
history of GI disease, previous or current drug abuse, or daily nicotine or alcohol 
consumption were included. They were randomized to receive either 1) oral PR 
oxycodone (10 mg twice on day 1 and 15 mg twice on day 2-5) and co-administered 
25 mg oral naloxegol (oxycodone+naloxegol) or matching placebo tablets 
(oxycodone+placebo). A flowchart of events in each treatment period is provided in 
Figure 3, and an overview on all experimental assessments and procedures is given in 
Figure 4.   
 
 
 
 
 
 
 
 
 
Figure 3. Overview on events in a treatment period of Study II. The grey fields represent events 
occurring outside of the research facilities. QST: quantitative sensory testing; MRI: magnetic 
resonance imaging; Oxy: oxycodone; Nalox: naloxegol; Pla: placebo.   
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Figure 4. Overview on all assessments and experimental procedures in Study II. MRI: magnetic 
resonance imaging; QST: Quantitative sensory testing; PAC-SYM: Patient assessment of 
constipation symptoms questionnaire; RAIR: Recto-anal inhibitory reflex. 
 
3.2.1.2   ANALGESIC EFFECTS 
 
 
Quantitative sensory testing was applied to assess whether naloxegol influenced the 
analgesic effect of oxycodone, hence this was measured on day 1 and day 6. A 
handheld algometre was used to apply pressure to the dorsal forearm until participants 
reached their pain detection threshold. Furthermore, in a cold pressor test the 
dominant hand was immersed in cold water (2 ºC) in 2 min, while participants 
continuously rated their pain intensity on a scale from 1-10.  
 
3.2.1.3   SELF-ASSESSED GASTROINTESTINAL SYMPTOMS 
 
 
Two questionnaires were used to provide continuous information on GI symptoms; 
The Patient assessment of Constipation Symptoms questionnaire (PAC-SYM) to 
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assess participant’s experience of constipation over time,78 and the BSFS to assess 
stool frequency and form.79 The participants filled in these questionnaires in the 
morning of day 1, every evening the next five days, and again in the morning of day 
6.  
 
3.2.1.4   ANAL SPHINCTER FUNCTION 
 
 
Anal sphincter function on day 1 and day 6 was evaluated by three assessments; anal 
resting pressure, the RAIR, and anal canal distensibility. A water-perfused pressure 
catheter was placed in the internal anal sphincter (IAS), and a latex balloon, composed 
as previously described and attached to a syringe was placed in the rectum.80 The 
balloon was inflated from 10 – 100 mL in a stepwise matter to elicit and measure the 
magnitude of RAIR, and anal resting pressure was measured as the IAS pressure five 
seconds before each distension (Figure 5A).81 The EndoFLIP, encountering a 
cylindrical distensible bag, measured anal canal distensibility as the bag was filled 
with a saline solution to reach a maximum level of 50 mL (Figure 5B).82 The bag 
pressure and anal canal diameter during the distension was used to assess pressure-
strain elastic modulus (a measure of stiffness) and yield pressure. 
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Figure 5. (A) Graphical illustration of measuring anal resting pressure and the recto-anal 
inhibitory reflex (RAIR) in relation to rectal balloon distension. The dotted lines represent start 
of balloon distensions. RAIR-induced sphincter relaxation was quantified as the difference in 
resting and residual pressure. (B) Screenshot from a typical EndoFLIP recording, here showing 
anal canal distensibility at 20-50 mL. Blue color indicates more pressure and thereby more 
constriction of the anal sphincter.  
 
3.2.1.5   COLONIC FECAL VOLUME 
 
 
To quantify total and regional volume of non-gaseous colonic content (feces) on day 
1 and day 6, an MRI scan of the lower abdomen was taken. Contiguous images (35-
40) were obtained using Dixon-type liver accelerated volume acquisition (LAVA-
flex) water-only scans during a single inspired breath hold of 20 sec. The scans were 
analyzed by an in-house semi-automatic data analysis software in which colonic 
regions of interests were manually outlined by the researcher (Figure 6).83,84 
Subsequently, a statistical classification approach was used to refine the segmentation 
of the colon, and determine the colonic fecal volume.  
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Figure 6. The procedure on outlining colonic regions to determine segmental colonic fecal 
volume. (1) The transition between the descending and recto-sigmoid colon was defined at the 
level of the left anterior superior iliac spine (red line). (2) Colonic regions were manually 
outlined, and (3) the automatic software crops the pixels to include only what is believed to be 
fecal matter, and volume was determined for each segment on each image.   
 
3.2.1.6   GASTROINTESTINAL TRANSIT TIME 
 
 
On day 2, the 3D-Transit electromagnetic capsule was swallowed and the abdominal 
belt was mounted to measure total and regional GI transit time and colonic motility 
patterns until day 6. Transit times were determined manually using analysis software 
in which capsule rotations and anatomical position of the capsule could be observed 
via 2D tracing (Figure 7A).85 Colonic segmental transit times were assessed using a 
graphical user interface. Furthermore, five colonic motor patterns were identified 
using an automatic algorithm; 1) mass movements; 2) fast antegrade movements; 3) 
slow antegrade movements; 4) slow retrograde movements; and 5) fast retrograde 
movements (Figure 7B), as previously described.86  
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Figure 7. (A) Screenshots from a typical 3D-Transit recording. Segmental transit times are 
determined by evaluating capsule rotations (as a proxy for contractions/minute, and the 
anatomical position as seen on the 2D plot. (B) Capsule progression through the colon. Blue 
dots indicate slow progression (1 dot/minute) and red lines indicate fast propulsions (mass 
movements of colonic content). CPM: Contractions/minute. 
 
3.2.2   KEY RESULTS 
 
 
Fifty-six responded to the recruiting material and 31 of these were found non-eligible 
(Figure 8). In total, 25 participants were screened and randomized. One participant 
was excluded after the first treatment period due to non-compliance, and replaced by 
mirror-randomization and thus, 24 participants (median age of 25 years) completed 
the study.  
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Figure 8. Flowchart for disposition of participants in Study II. 
 
3.2.2.1   ANALGESIC EFFECTS 
 
 
For both treatments, the analgesic effect of oxycodone was validated with a 15-19% 
increase in pain detection threshold to muscle pressure on day 6, compared to baseline 
(all P < 0.02). Naloxegol did not reverse this analgesic effect, as there was no 
difference in pain detection threshold on day 6 between treatments (P > 0.1). For the 
cold pressor test, it was not possible to detect an analgesic effect of oxycodone in 
either treatment-arms (all P > 0.05) (Study IIa-IIb).  
 
3.2.2.2   SELF-ASSESSED GASTROINTESTINAL SYMPTOMS 
 
 
GI symptoms increased over days in both treatments. Compared to placebo, naloxegol 
decreased PAC-SYM questionnaire scores, and improved stool form (i.e. induced 
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softer stools), a significant difference confined to day 3 (Figure 9A-B). There was no 
difference in stool frequency between treatments (P > 0.05) (Study IIa-IIb).  
Figure 9 (A). Progression of GI symptoms over the course of 6 days in each treatment arm, 
assessed by The Patient assessment of Constipation Symptoms questionnaire (PAC-SYM) The 
differences reached statistical significance at days 5-6. (B) Results from the Bristol Stool Form 
Scale (BSFS) depicting stool form (lower scores represent harder, drier stools, i.e. 1 = 
constipation; 7 = diarrhea). Data are presented as means ± SEM. 
 
3.2.2.3   ANAL SPHINCTER FUNCTION 
 
 
Neither anal resting pressure nor anal canal distensibility were affected by either 
treatment (all P > 0.05). Compared to baseline, RAIR was diminished after 6 days of 
oxycodone treatment, and this effect was reversed by naloxegol, an effect significant 
at rectal balloon volumes of 60-100 mL (Figure 10) (Study IIa).  
 
 
Figure 10. The effect of the two treatments on relaxation pressure (i.e. drop in internal anal 
sphincter pressure following balloon distension), in which naloxegol treatment normalized 
oxycodone-induced diminish of the recto-anal inhibitory reflex. The P-value represents 
differences between the two treatment arms, and data are presented as means ± SEM. 
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3.2.2.4   COLONIC FECAL VOLUME 
 
 
Compared to baseline, colonic fecal volume was higher on day 6 in both treatments 
(all P < 0.001), and naloxegol did not reduce this volume on day 6, compared to 
placebo (P > 0.2) (Figure 11A) (Study IIb).  
 
3.2.2.5   GASTROINTESTINAL TRANSIT TIME 
 
 
3D-Transit capsule retention on day 6 occurred in 3 out of 24 cases during 
oxycodone+naloxegol treatment and 8 out of 24 cases during oxycodone+placebo. 
Compared to placebo, naloxegol reduced oxycodone-induced prolongation of total GI 
transit time (P=0.02) and colonic transit time (P<0.01) in which the significant 
difference was confined to the recto-sigmoid segment (Figure 11B). No difference in 
colonic motility parameters were found (all P > 0.1) (Study IIb). 
 
Figure 11. (A) Differences in total colonic fecal volume from day 1-6. (B) Total and 
segmental transit times. Data are presented as means ± SEM. 
 
3.2.2.6   ASSOCIATIONS BETWEEN MEASURES 
 
There were no significant associations between PAC-SYM scores, stool frequency or 
form, segmental transit times, colonic fecal volumes, or the anal sphincter 
measurements in either of the two treatments (Study IIa-IIb).  
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3.3   STUDY III  
 
 
Regional transit times obtained by the 3D-Transit system is determined by visually 
observing changes in capsule rotation, along with shifts in position, as it passes the GI 
tract. However, mostly due to motion artefacts, these time points can be very difficult 
to identify, especially for the untrained eye. The 3D-Transit system possesses great 
potential in assessing GI motility, however, the validity of this manual method has not 
yet been addressed in detail. Hence, in this study we evaluated the inter-and intra-rater 
reliability of segmental transit times and addressed how the experience of raters 
influenced the identification of transit times.  
 
3.3.1   METHODS 
 
 
An overview on the study design of Study III is provided in Figure 12. Three 
researchers from Aalborg and London with different levels of experience in analyzing 
3D-transit system data took part in this study. From a local research database, 36 
recordings of healthy participants were randomly selected for analysis. All raters used 
a standardized procedure to place landmarks in the 3D-Transit System software to 
identify the time points when the ingestible capsule progresses from the stomach to 
the small bowel (gastric emptying), to the cecum (small bowel transit time), and out 
(colonic transit time). The analyses were repeated after a minimum time gap of two 
weeks. For each time point identified, the time taken, and difficulty of placing the 
landmarks were documented. Inter- and intra-rater reliability were determined using 
the intraclass correlation coefficient.   
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Figure 12. Simplified design of Study III. 
 
3.3.2   KEY RESULTS 
 
 
Inter-rater reliability comparing measurements for all three raters was poor for gastric 
emptying and small bowel transit time, although, fair between the two most 
experienced raters (ICC = 0.41 – 0.47) (Figure 13). For colonic transit time, inter-rater 
reliability was excellent for all measurements and in between raters (ICC = 0.94). For 
the two experienced raters, good to excellent intra-rater reliability was found for 
gastric emptying and small bowel transit time (ICC = 0.84 -1.00), while agreement 
was poor for the least experienced rater (0.20-0.48). Excellent intra-rater reliability 
was found for all three raters for colonic transit time (ICC = 0.97-0.99) (Study III).  
 
Figure 13. Combined scatterplots for inter-and intra-rater reliability across raters for (A) 
gastric emptying transit times (GTT), (B) small bowel transit times (SBTT), and (C) colonic 
transit times (CTT). Green color is the most experienced rater, red color is the mid-
experienced rater, and blue color is the least experienced rater.  
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CHAPTER 4   DISCUSSION 
 
Section 4.1 discusses the establishment of an experimental model to mimic OIBD, 
and the potential of such a model to clarify underlying mechanisms of OIBD and how 
pharmacological agents may treat it. Hereafter, a discussion on feasibility, advantages 
and limitations of subjective and objective assessments to evaluate OIBD is provided 
in section 4.2 and 4.3, undertaking the results from Study II and III.  
 
4.1   HUMAN EXPERIMENTAL OIBD MODELS 
 
In general, the purpose of experimental models is to mimic a specific symptom or 
disease in a reversible manner. This generates a controlled setting in which underlying 
pathological mechanisms, or responses to pharmacological interventions can be 
thoroughly investigated as in Study II. In animal models, the primary usage is in 
pharmacological studies to evaluate the safety and efficacy of novel and existing 
compounds in e.g. the opioid-affected rodent or primate gut.87 However, due to the 
substantial species differences, interpolation of findings from animal studies to man 
is not always feasible. Human experimental models are therefore an important tool in 
translation from animal research into clinical implications. A valid human model must 
induce the same or similar symptomatology associated with the relevant disease, and 
this also applies with GI models. Various in vivo models of GI symptoms exist, e.g. 
for gut hyperalgesia, acid-related esophageal diseases, and diarrhea.88–90 In contrast, 
inflammatory GI diseases are very difficult to mimic in humans, partly due to their 
multifactorial etiology and complex symptomatology, but also due to ethical reasons. 
This vastly limits models of e.g. irritable bowel syndrome, Crohn’s disease, and 
ulcerative colitis to be induced in animals.91 
    As OIBD is not a disease in itself, but induced GI side effects to an intervention, 
the establishment of a human experimental OIBD model may seem straightforward. 
As previously mentioned, such a model was recently established by Poulsen et al. and 
Nilsson et al.76,77 Lately, this model was employed in a comparative study to assess 
the efficacy of two treatments; Combined PR oxycodone and PR naloxone (an non-
selective opioid antagonist) vs macrogol 3350 (a conventional laxative), on GI 
motility and anal sphincter function.92,93 A very similar model was applied in Study 
II, in which the dose of oxycodone was slightly higher (30 mg instead of 20 mg pr. 
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day), and treatment period was six days instead of five. These changes were applied 
to ensure sufficient OIBD manifestation in order to detect a possible effect of 
naloxegol. As various GI symptoms were induced, and GI transit time in both 
treatment periods were considerably longer than placebo values from the study by 
Poulsen et al, we concluded that an OIBD model was indeed established in Study II. 
Not only oxycodone can be used to induce symptoms of OIBD in healthy participants 
for the purpose of measuring a pharmacological effect of a PAMORA. Thus, a 3-day 
treatment period of 12 mg b.i.d codeine in healthy has been used to show a reversal 
of codeine-induced prolongation of small intestine and colonic transit by alvimopan.26 
The same approach was used by another research group in which methylnaltrexone 
was found to have no effect on codeine-induced prolongation of colonic transit.94 The 
authors of the latter study suggested that a higher dosage of methylnaltrexone may be 
needed to induce a detectable effect on transit in opioid-naïve healthy participant, 
however they did not question the model itself.   
 
4.1.1   ADVANTAGES AND LIMITATIONS OF OIBD MODELS 
 
The application of experimental models for the study of pharmacological effects on 
OIBD symptoms has several important advantages. For example, the influence of 
confounding diseases, psychological factors, and other administrated drugs is 
eliminated, and we are able to study OIBD in a much more controlled setting. In 
clinical settings, patients with OIBD always has one or more disorders associated with 
severe pain, demanding the initial opioid analgesic treatment. However, patients 
(especially in the elderly generation) may not only be suffering from pain, but also 
have other disorders known to induce GI dysfunction and chronic constipation, e.g. 
type 2-diabetes and Parkinson’s disease.95,96 Furthermore, patients with OIBD are 
highly susceptible to psychological distress including both global distress and 
anticipatory anxiety.97,98 Psychological distress is known to induce GI symptoms in 
itself, possibly creating a vicious circle. In general, pain and stressful states is known 
to evoke both short- and long-term influences on function of the GI tract.99 Finally, 
many OIBD patients are likely treated with additional drugs known to affect GI 
motility, such as NSAIDs, antihypertensive agents, and tricyclic antidepressants.100,101 
All these comorbidities are vastly avoided in experimental OIBD models (Figure 14). 
Nevertheless, several limitations need to be addressed as the degree to which a very 
short-term model can mimic processes involved in clinically OIBD is debatable. First 
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of all, OIBD patients are often treated with higher opioid doses and for a much longer 
period of time than what is feasible and ethical in studies with healthy participants. 
Opioids are highly addictive substances, and several ethical considerations needs to 
be taken into account when administrating these drugs to healthy participants. Hence, 
in study II, strict exclusion criteria concerning present or previous use of addictive 
substances (nicotine, alcohol, illegal drugs) were applied. Moreover, early signs of 
opioid dependency were assessed by the study personal three days after a treatment 
period was ended (no participants showed any initial dependency signs during or after 
any treatment period). An experimental model involving the GI tract also needs to 
sustain from causing prolonged alterations in either intestinal histology of GI motility. 
For the time however, we do not know whether a short-lasting treatment period of 
opioids cause long-term alterations in gut motility function, however we do consider 
the dosage and length of treatment in Study II to be completely reversible and safe.  
Figure 14. Schematic overview on the most important confounders in clinical studies of 
OIBD, and how these are avoided in experimental OIBD models. In experimentally induced 
OIBD, the response to pharmacological interventions can be assessed with 
subjective/objective methods like in Study II.  
 
4.2   SUBJECTIVE ASSESSMENTS OF OIBD 
 
Pain and discomfort are personal, subjective experiences influenced by the situation, 
cultural background, and various psychological variables.102 This also applies to the 
patient’s view on opioid-induced GI side effects. In clinical practice, knowledge on 
patient experience of OIBD symptoms is crucial in all aspects of diagnostics and 
choice of treatment, and several self-assessed questionnaires and rating scales for 
evaluating constipation/OIBD in the clinic have been developed over the past years. 
All are primarily focusing on self-reports on constipation intensity/severity, 
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ease/difficulty of defecation, incomplete evacuation, straining and satisfaction (i.e. 
satisfaction with stool frequency or pharmacological treatment).103 The most widely 
used questionnaire is probably the Bowel Function Index, which is very 
straightforward and easy to use in daily clinical practice.104 Some questionnaires are 
more time-consuming and prone to non-compliance thus primarily adapted for 
research purposes. These include the Cleveland Clinic Constipation Score, 
Constipation assessment scale, the Patient Assessment of Constipation-Quality of 
Life, Gastrointestinal Symptom Rating Scale, and PAC-SYM, all well-validated and 
assessing a wide range of GI symptoms related to OIBD.105 For multiple reasons, the 
PAC-SYM questionnaire was chosen as the single subjective measure in Study II. 
First of all, the PAC-SYM has high internal consistency and high test-retest 
reliability.78 Second of all, as a distinct advantage, the PAC-SYM questionnaire is 
divided into three symptom domains; abdominal symptoms (four questions), rectal 
symptoms (three questions), and stool symptoms (five questions), and therefore 
provides a broad picture on all aspects of OIBD. Third of all, several studies have 
found PAC-SYM to efficaciously detect not only negative opioid-effects on GI 
symptoms, but also efficacy of various pharmacological agents to treat it.46,76,106 In 
Study II, we found progressively increasing GI symptoms during the course of 
oxycodone treatment, and comparing naloxegol and placebo, participants receiving 
naloxegol had fewer GI side effects. This supports the clinical efficacy of naloxegol 
to treat OIBD symptoms, and the results are also in line with a previous comparable 
study in which naloxegol improved PAC-SYM scores of non-cancer pain patients 
receiving high doses of opioids.62 However, as with all other questionnaires to 
evaluate OIBD, the PAC-SYM only provide a snapshot of a very subjective feeling, 
and results rely heavily on the participants understanding of the terminology utilized 
in the questionnaires. A limitation regarding Study II was that GI symptoms were not 
recorded prior to start of each study period, which could have increased the validity 
of the PAC-SYM results.   
    Several attempts have been made to prove a correlation between self-reported GI 
symptoms and objective measures such as transit time. Such correlations could, in the 
long run, justify that clinicians and researchers merely use subjective measures, 
thereby probably increasing compliance and reducing clinical trial costs. In Study II, 
the PAC-SYM results did not correlate to the length of transit times (or RAIR-induced 
sphincter relaxation), which is in line with previous studies investigating the 
association between PAC-SYM and transit time in constipated individuals.73,74,107 
This indicates that the individual perception of OIBD is independent of objective 
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findings, which reflects the multifactorial clinical representation of OIBD. Thus valid, 
easy applicable, and low-cost objective methods are still needed in both clinical 
settings and research trials to assess OIBD.  
 
4.3   OBJECTIVE ASSESSMENTS OF OIBD 
 
4.3.1   STOOL FREQUENCY AND FORM 
 
The BSFS is a visual scale allowing the patient/participant to identify form of stool 
using seven different images with anchored words.79 If used over a longer period of 
time, the BSFS may also be used to evaluate daily/weekly stool frequency. As touched 
upon in Chapter 2, stool frequency and form are often applied in the clinic to evaluate 
OIBD severity, and these outcomes continue to be used as surrogate markers of bowel 
transit/motility, despite limited validation. Especially in research, stool frequency is 
not recommended as the sole outcome when evaluating OIBD, for three overlapping 
reasons: Firstly, stool frequency is likely affected by multiple factors that are difficult 
to control for i.e. dietary intake, activity level, psychological state etc. Secondly, stool 
frequency does not always associate with symptom burden, and may be normal in 
even heavily constipated patients.5 Thirdly, stool frequency rarely correlates with 
other more objective measures, e.g. whole-gut transit as found in studies with patients 
with chronic constipation and irritable bowel syndrome.79,108 On the other hand, stool 
form may be a much better predictor of whole-gut transit (and indicator of general 
bowel health), although patients may find evaluating stools via the BSFS difficult.109 
Altogether, because stool frequency is very variable even in healthy (3-11 stools per 
week in adults110), and stool characteristics also can vary substantially, BSFS 
outcomes should always be accompanied by other more objective testing modalities. 
    In Study II, we found a mean stool frequency of 0.5 pr. day for participants 
receiving oxycodone+placebo treatment. As the most common bowel habit is 
considered once daily, these results indicate that oxycodone decreased stool 
frequency.111 Our results are also comparable to the preceding study by Nilsson et al., 
who reported a frequency of 0.8 after 5 days of oxycodone treatment.77 The small 
difference may reflect the slightly higher oxycodone dosage and longer treatment 
period in Study II. Although a trend was present, we found no significant effect of 
naloxegol on stool frequency (0.68 vs 0.5 daily spontaneous bowel movements). This 
conflicts earlier studies in which 4-12 weeks of naloxegol treatment increased weekly 
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stool frequency in OIBD patients.61,112 As these studies employed chronic opioid 
users, it is very plausible that such a short-term treatment applied in Study II is too 
small to affect stool frequency. On the other hand, naloxegol did induce softer stools, 
as the mean daily BSFS score was 3.6 compared to 2.9 for placebo. The physiological 
explanation is probably linked to improvement of motility and reduced passive 
absorption of gut fluids. A recent paper on data from the KODIAC studies also 
reported that naloxegol improved stool form over a course of 12 weeks.71 Our findings 
can be considered very clinically relevant, as patients often relate their OIBD burden 
to uncomfortable passing of dry, hard stools.41  
 
4.3.2   THE 3D-TRANSIT SYSTEM  
 
 
As mentioned in Section 3.2, commonly used methods for assessing GI motility are 
scintigraphy, radiopaque markers, and hydrogen breath tests, all mainly applied for 
the measurement of whole gut transit time. The purpose of Study II was to explore the 
exact motility changing effects of a PAMORA, and where in the GI tract these 
changes were most pronounced. For this purpose, the 3D-Transit is currently the most 
advanced tool on the marked, hence this methods was applied. This system accurately 
tracks and measures the position of up to three ingestible electromagnetic capsules 
throughout the GI tract, via an external detector plate carried on the abdomen.85,113 As 
depicted in Figure 7A, regional transit times are hereafter manually identified by 
visually observing changes in the orientation angles of the capsule, reflecting gut 
peristalsis. However, due to external movements and external noise, it can be very 
difficult to identify the time points from when a capsule progresses from one GI 
segment to the other. The inter-rater reliability of manually assessed GI transit times 
has been reported to be very good.85 However, the raters in this study were not blinded 
to each other’s analyses, and helped each other analyze difficult recordings. Study III 
was conducted to assess the intra-and inter-rater reliability of regional GI transit times 
in a blinded fashion, between raters with various experiences. This was done to 
validate the results on transit time outcomes from Study II, and to provide 
recommendation for future studies using the 3D-Transit system. Our results showed 
that raters need adequate and long-term training in identifying the transition from one 
GI segment to the other, as the inexperienced rater provided transit times with very 
low reliability.  
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    The 3D-Transit system has previously been used to gain insights into regional GI 
dysmotility in patients with carcinoid diarrhea, severe ulcerative colitis and 
Parkinson’s disease.75,114,115 Regarding experimental OIBD, the 3D-Transit system 
was also used in the study by Poulsen et al., to prove the prolongation of transit by 
oxycodone.76 Comparing the total GI transit time for oxycodone+placebo treatment 
in that study and Study II, transit time was considerable longer in the latter (71.3 hours 
vs 43.9 hours). This emphasizes that we succeeded in establishing an OIBD model in 
terms of prolonging transit. Only a few studies have investigated the effect of 
naloxegol on opioid-induced prolongation of transit time, as the main focus until now 
has been to prove a more clinical-related effect of the drug, e.g. increased stool 
frequency. In Study II, naloxegol treatment significantly reduced total GI transit time, 
compared to placebo (56.8 hours vs 71.3 hours). Compared to placebo treatment in 
the study by Poulsen et al, which did not include oxycodone administration, naloxegol 
did not completely reverse transit time to “normal levels” (56.8 hours vs 22.2 hours). 
However, to verify this comparison we would need a strict placebo-arm in Study II, 
which was not included in the study design. Our findings are in line with a study 
employing the hydrogen breath test to conclude that naloxegol reduce morphine-
induced prolongation of transit time in healthy participants.63 In contrast, our result 
are in conflict with a very recent study by Halawi et al. finding that 3 days of 25 mg 
naloxegol treatment in healthy participants does not reverse codeine-induced 
prolongation of whole gut transit as measured with scintigraphy.70 This might question 
whether a higher dose of naloxegol may be needed to treat OIBD resulting from acute 
opioid administrations, reinforced by a previous study showing that morphine-
prolongation of transit time in healthy participants was significantly reduced by 
naloxegol only when administered as dosages of 125 mg or higher.116 The 
discrepancies between our studies could also lie within the study designs, as the study 
by Halawi et al. used a relatively low dose of the pro-drug codeine, and only for 3 
days. Furthermore, although scintigraphy is considered the golden standard for transit 
measurements, a limitation for this method is that transit time is based on snapshot 
images of the colon obtained after 24 and 48 hours of ingesting a radiolabeled solid. 
In Study II, most transit times were in the range of 60-90 hours, and therefore 
scintigraphy likely underestimates transit times for the most constipated participants, 
who might also have the greater effect of naloxegol treatment. This problem is 
eliminated with methods employing ingestible capsules like the 3D-Transit system. 
Furthermore, with this system it is possible to assess regional transit times, not only 
for the stomach, small bowel, and colon, but also for the four colonic segments. In 
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Study II, naloxegol significantly reduced transit time in the recto-sigmoid segment 
(9.2 hours vs 23 hours in the placebo treatment). This may be because naloxegol 
promotes colonic motility, leading to less stasis of stool in this GI region thereby 
making stool less dry and hard easing defecation. Also, it may point to that opioid-
induced anal sphincter dysfunction is somewhat reduced by naloxegol which will be 
discussed in section 4.3.4.  
    The 3D-Transit system has the potential to measure various colonic motility 
patterns, e.g. number of colonic mass movements, proportion of antegrade, retrograde, 
fast and slow peristaltic movements. Colonic transit time presumably reflects 
underlying motility, hence, as naloxegol decreased colonic transit time, we expected 
to find increased colonic motility parameters as well. However, no differences 
between the two treatments were found. The method to evaluate colonic motility 
patterns with the 3D-Transit system is still in its infancy. However, from a very recent 
study employing the 3D-Transit system we know that oxycodone does cause colonic 
dysmotility, in that a 5-day oxycodone treatment induced less colonic mass 
movements in healthy participants.32 Colonic motility parameters has previously been 
addressed in a study by Hiroz et al., which was designed to capture colonic responses 
to stimuli known to enhance gut motility in healthy participants.117 Compared to this 
study, we found considerably less values for colonic activity in Study II. However, in 
the Hiroz et al. study, colonic motility was assessed in immobilized healthy 
participants, using the preceding stationary MTS-1 system. Hence, whether the 
discrepancy ascribes the presumed dampening effect on motility by oxycodone, or 
differences in methodology, cannot be known for sure. 
 
 
4.3.3   MRI COLONOGRAPHY 
 
 
Like stool frequency and GI transit time, colonic volume may also be considered a 
surrogate marker for underlying GI motility. Theory is, the less forward propulsive 
motility, a larger volume of fecal matter accumulates in colon which leads to more 
constipation. In the clinic, assessment of colonic volume may be beneficial to evaluate 
constipation in terms of assessing the degree of fecal retention and the need for 
disimpaction before therapy. For this, a standard abdominal x-ray is often used.118 
Furthermore, abdominal CT imaging can provide a more virtual colonography which 
is useful for evaluating colonic content in relation to bloating and abdominal 
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distension.119 However, a CT requires either colonic gas filling or contrast 
enhancement, and therefore exposes the patient to substantial discomfort and 
potentially harmful ionizing radiation.120 MRI produces images without the use of 
contrast-enhancing agents in the unprepared colon, which facilitates the quantification 
of segmental colonic volumes in a non-harmful manner. MRI has previously been 
used to measure fasting and postprandial small and colonic volumes in healthy and 
patients with IBS.121–124 Although not applied in the clinical evaluation of OIBD (to 
our knowledge), MRI colonography represents a valuable tool for the evaluation of 
OIBD in research. For this purpose, our research group has recently developed an in-
house semi-automatic software capable of calculating segmental colorectal volumes 
from T2-weighted MRI images, a method shown to have a high degree of validity.65,106 
This was applied to show an increase in colonic volume after 5 days of oxycodone 
treatment in healthy participants in the study by Nilsson et al. (a 41% increase in 
cecum/ascending colon compared to placebo treatment).77 Also, the same method was 
used in a recent study in which oxycodone-treated participants receiving the osmotic 
laxative macrogol had a significantly higher colorectal volume, than those receiving 
naloxone.92 However, using T2-weighted MRI images has limitations in that colonic 
gas and the colon wall itself are also interpreted as colon volume. Thus these images 
are unable to determine the “true” volume of fecal matter. This may however be 
obtained using LAVA-Flex MRI sequences, which eliminates the possibility of 
interpreting gas and intestinal wall erroneously as feces.125,126 This method has been 
shown to offer a superior and more homogenous fat suppression of the abdomen 
compared to a standard T1-weigthed MRI.127 Thus, the MRI images obtained in Study 
II was analyzed as LAVA-Flex sequences. In line with the previous study by Nilsson 
et al. using T2-weghted images,77 we found a significant increase in colonic fecal 
volume after 6 days of oxycodone treatment in Study II. We assumed that colonic 
fecal volume would be somewhat reliant on GI transit time, however volume did not 
differ between naloxegol and placebo treatment. An explanation for this may be that 
naloxegol simply doesn’t affect colonic volume to an extent that is measureable with 
MRI. Another possible explanation however is linked to the proposed effect of 
naloxegol on opioid-induced fluid secretion/absorption dysfunction as explained in 
section 1.3. Thus, colonic fecal volume could be counterbalanced to the level of 
placebo treatment as naloxegol may increase the amount of water in colonic contents, 
which may be interpreted as high fecal load on the MRI images. However, colonic 
volume obtained by LAVA-Flex sequences is not (yet) a validated method, and the 
MRI results from Study II should therefore be considered preliminary. Further 
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refinement on the analysis of colonic water content is also necessary to confirm this 
theory. For this, texture analysis of MRI images could be the way forward as applied 
in a study investigating the effect of loperamide (an opioid sold as an anti-diarrhoeal 
agent) on small bowel water content.128 Another explanation for the MRI findings in 
Study II is methodological limitations. Several MRI scans were missed due to 
retention of the 3D-Transit capsule (as the capsule is not approved for the MRI 
scanner), thus only 15/24 and 19/24 scans on day 6 were obtained for the naloxegol 
and placebo treatment, respectively. This probably systematically underestimates 
colonic fecal volume in especially the placebo treatment arm, as the participants in 
this group would likely the more constipated.  
 
4.3.4   ASSESSMENT OF ANAL SPHINCTER FUNCTION 
 
 
Anal sphincter function in relation to constipation may be assessed with a variety of 
objective methods. In the clinic, an underlying evacuation disorder is often confirmed 
or ruled out using a defecography, endo-anal ultrasound, or a balloon expulsion test 
to assess anorectal and pelvic floor motion129 In addition, anorectal manometry 
(conventional, high-resolution, and 3D-high definition) is the most widely used 
technique for the detection of abnormalities of sphincter function or recto-anal 
coordination.130 With this, anal resting pressure, maximal pressure during sustained 
voluntary contraction, duration of sustained voluntary contraction, and pressure 
during cough reflex can be assessed.131 Sphincter function is rarely a part of the 
clinical evaluation of OIBD although straining and discomfort during evacuation are 
common symptoms. Thus, a study in opioid-treated patients, one-third had the 
sensation of anal blocking and often felt the need to use digital maneuvers to complete 
defecations.41 A part of the explanation as to why clinicians rarely focus on opioid-
induced anal sphincter dysfunction may be that studies on this area are highly 
inconclusive and relatively old. Thus, two studies report that opioids elevate anal 
sphincter tone132,133, while all others conclude that opioids have no effect.39,93,132–135 
All these studies used simple anorectal manometry which was also applied in Study 
II. Here, we also found no effect of oxycodone on anal resting pressure, and thus also 
no effect of naloxegol compared to placebo. The distribution and physiological 
importance of opioid receptors in the structures of the IAS and external anal sphincter 
is not clarified.136 Thus, a simple reason for this finding may be that opioid receptors 
are not present in the myogenic structures of the smooth muscle that produce the basal 
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tone of the anal sphincter.137 Other explanations for these results are that such a short 
duration of treatment is not enough to affect anal pressure, or that the differences in 
anal resting pressure between baseline and 6 days pharmacological treatment may be 
too small to detect using simple anorectal manometry. An effect was however 
observed on the RAIR in that 1) oxycodone treatment significantly diminished the 
RAIR, and 2) naloxegol returned this to normal level. The former is in line with a 
study by Poulsen et al. who found oxycodone to diminish RAIR after 5 days 
treatment,31 and with an older study using loperamide.116 The physiological 
explanation behind this effect on RAIR may be that opioids hyperpolarize the 
intramural enteric neurons,33 or due to an effect of opioids on the conscious perception 
of stool in the rectum.39 This dampening effect of opioids on perception of rectal 
filling and ability of IAS relaxation may contribute to the symptomatology of OIBD 
and hinder normal defecation. The normalizing effect of naloxegol on RAIR is likely 
explained by the elimination of oxycodone molecules from the high density of opioid 
receptors in the neural structures of the IAS.138 The method used to assess RAIR in 
Study II is inspired from the study by Musial et al., as a very quick and simple way to 
quantify the drop in IAS pressure following a rectal distention.39 However, limitations 
with this method are difficulties in manually securing the correct placement for the 
rectal balloon, and that position of the participant and the presence or absence of the 
perception of the desire to defecate possibly have an influence on the absolute values 
obtained. Also, these measurements are performed in the unprepared rectum which 
means that accumulating stool could prevent the filling of the balloon in especially 
the most constipated participants, which could provide erroneously pressure data. A 
better and more standardized method to assess both anal resting pressure and the 
RAIR would have been high-resolution anorectal manometry which can provide a 
much better visualization and direct assessment of the recto-anal coordination.139 This 
method may be more sensitive to clinically relevant pathology than anorectal 
manometry.140 In addition to manometry evaluating anal sphincter tone and RAIR we 
applied the EndoFLIP to evaluate distensibility of the entire sphincter apparatus 
following the pharmacological treatments. However, our group has yet been 
unsuccessful in proving an effect of opioids on anal canal distensibility using the 
EndoFLIP,93 and this was also the case for Study II. These findings suggest that 
opioids does not affect distensibility and stiffness of the anal canal, and thereby this 
method was not appropriate to detect effects on naloxegol on this either. Most likely, 
the EndoFLIP system is a more suitable method in the detection of large distensibility 
deficiencies, and is not suitable to detect very small changes in distensibility as a 6 
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day opioid treatment probably would produce. Thus, the EndoFLIP system has 
previously been used to evaluate anal sphincter function in patients with profound 
defactory disorders such as fecal incontinence and systemic sclerosis affecting the 
smooth muscle cells of the IAS.141,142 
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CHAPTER 5   CONCLUSION 
 
Naloxegol not only improved GI symptoms, but also reversed opioid-induced 
dysmotility and opioid-induced dampening of the RAIR. Thus, self-assessed 
questionnaires, the 3D-Transit system, and assessment of RAIR through anorectal 
manometry were all methods sensitive enough to detect an effect of a PAMORA on 
experimentally induced OIBD. When setting up future studies investigating OIBD, in 
which one wants to comprehend many different areas of the GI tract, researchers could 
beneficially focus on these methods. Especially the 3D-Transit system holds great 
potentials within obtaining detailed information on intestinal motility, and results 
from Study III validates and supports the current methodology for the extraction of 
segmental transit time from its software. The EndoFLIP system does not seem suitable 
for these kind of experimental studies. On the other hand, RAIR seems to account for 
a part of the defactory problems seen in OIBD, and the method using anorectal 
manometry and balloon distension of the rectum appears feasible. Although no effect 
of naloxegol was seen on colonic fecal volume, the method of MRI colonography 
holds potential for improvement and may be a suitable method when investigating 
how opioids affects colonic fecal volume. 
 
5.1   FUTURE PERSPECTIVES 
 
 
This thesis provides the framework for further development of methods to assess 
OIBD, and for various types of new studies. As mentioned in the introduction, the 
efficacy outcome in previous studies of naloxegol has primarily been change in 
number of bowel movements, and not much is known on the underlying mechanisms 
of this drug. Thus, the next natural step would be to evaluate the effect of naloxegol 
in chronic opioid users using questionnaires, the 3D-Transit system, and assessment 
of RAIR as applied in Study II. These methods could also be applied in studies 
investigating other conditions where GI dysmotility or anal sphincter dysfunction is 
suspected, e.g. in patients with irritable bowel syndrome or Crohn’s disease. 
Moreover, we intend to further examine the possibilities within MRI to assess water 
content in colon, not only to be applied for the MRI data in Study II, but to be used as 
a general elucidative and diagnostic tool when assessing OIBD in clinical settings. 
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Also, for the 3D-Transit system, we intend to advance data analysis of the colonic 
motility parameters obtained with this system, and possibly conduct new studies on 
how naloxegol affect specific motility patterns in colon. Refinement of the MRI 
method and the 3D-Transit system could provide important knowledge regarding how 
gut secretory and motility mechanisms are affected by opioids, and how this is 
modulated/normalized by e.g. PAMORAs.  
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